The poor norepinephrine innervation and high density of Gi/o-coupled α 2A -and α 2C -adrenoceptors in the striatum and the dense striatal dopamine innervation have prompted the possibility that dopamine could be an effective adrenoceptor ligand. Nevertheless, the reported adrenoceptor agonistic properties of dopamine are still inconclusive. In this study, we analyzed the binding of norepinephrine, dopamine, and several compounds reported as selective dopamine D 2 -like receptor ligands, such as the D 3 receptor agonist 7-OH-PIPAT and the D 4 receptor agonist RO-105824, to α 2 -adrenoceptors in cortical and striatal tissue, which express α 2A -adrenoceptors and both α 2A -and α 2C -adrenoceptors, respectively. The affinity of dopamine for α 2 -adrenoceptors was found to be similar to that for D 1 -like and D 2 -like receptors. Moreover, the exogenous dopamine receptor ligands also showed high affinity for α 2A -and α 2C -adrenoceptors. Their ability to activate Gi/o proteins through α 2A -and α 2C -adrenoceptors was also analyzed in transfected cells with bioluminescent resonance energy transfer techniques. The relative ligand potencies and efficacies were dependent on the Gi/o protein subtype. Furthermore, dopamine binding to α 2 -adrenoceptors was functional, inducing changes in dynamic mass redistribution, adenylyl cyclase activity, and ERK1/2 phosphorylation. Binding events were further studied with computer modeling of ligand docking. Docking of dopamine at α 2A -and α 2C -adrenoceptors was nearly identical to its binding to the crystallized D 3 receptor. Therefore, we provide conclusive evidence that α 2A -and α 2C -adrenoceptors are functional receptors for norepinephrine, dopamine, and other previously assumed selective D 2 -like receptor ligands, which calls for revisiting previous studies with those ligands.
Introduction
The neurotransmitter norepinephrine (NE) binds and activ a t e s t h r e e s u b f a m i l i e s o f a d r e n o c e p t o r s : α 1 -adrenoceptors, subdivided into α 1A , α 1B , and α 1D ; α 2 -adrenoceptors, subdivided into α 2A , α 2B , and α 2C ; and β-adrenoceptors, subdivided into β 1 , β 2 , and β 3 [1] . Classically, α 1 -, α 2 -and β-adrenoceptors couple to Gq/ 11, Gi/o, and Gs, respectively [1, 2] . In mammalian species, α 2A is the main subtype in most brain regions whereas α 2B subtype has a limited distribution and is mostly expressed in the thalamus [3, 4] . The α 2C subtype is found with particularly high density in the striatum [5, 6] with a moderately lower density than α 2A [7, 8] . The high density of dorsal striatal α 2A -and α 2C -adrenoceptors prompted a fundamental question in view of the well-known paucity of striatal noradrenergic terminals [9] [10] [11] and the concomitant low extracellular levels of striatal NE [12] . Yet, a series of studies indicate that both types of receptors are fully Marta Sánchez-Soto and Verònica Casadó-Anguera contributed equally to this work.
functional in the striatum, where they seem to be localized mostly postsynaptically, preferentially in GABAergic striatal efferent neurons [13, 14] . There is also evidence for α 2A -adrenoceptors playing a role as autoreceptors localized in the sparse striatal noradrenergic terminals [15] . It was postulated by Zhang et al. [16] that dopamine (DA) could provide the endogenous neurotransmitter for striatal α 2 -adrenoceptors. In transfected mammalian cells, using radioligand binding experiments, they found only a small preferential affinity of NE versus DA at both α 2A -and α 2C -adrenoceptors. Similar results were more recently obtained from radioligand binding studies using transfected mammalian and insect cell lines [17] and with radioligand binding and autoradiographic experiments in the bird and rat brain with a non-selective α 2 -adrenoceptor ligand [18] . However, Zhang et al. [16] reported a much lower potency of DA (in the micromolar range) than NE (in the nanomolar range) at the level of α 2C -adrenoceptor-mediated signaling (modulation of forskolin-induced adenylyl cyclase activation).
Due to the mismatch between dopaminergic and noradrenergic innervation and the density of their receptors in several brain areas, the controversy about the differential binding affinity of DA versus NE on adrenoceptors, and the potential functional efficacy of this binding, we wanted to study in detail the ability of DA and several synthetic DA receptor ligands to bind to the orthosteric site of α 2 -adrenoceptors in transfected cells and in the sheep brain. Moreover, we further analyzed the ability of these ligands to generate functional responses: activation of G proteins, inhibition of cAMP accumulation, and ERK1/2 phosphorylation. In the present study, we first analyzed the ability of DA and several DA receptor ligands to bind to α 2 -adrenoceptors in cortical tissue, which predominantly expresses α 2A -adrenoceptors, and in striatal tissue, which expresses both α 2A -and α 2C -adrenoceptors. We also studied the potential dopaminergic function of α 2A -and α 2C -adrenoceptors using the same methodology that recently allowed us to demonstrate the potent activation of all Gi/o-coupled DA D 2 -like receptors by NE [19] . This methodology consists on sensitive bioluminescence resonance energy transfer (BRET)-based techniques that allow detection of ligand-dependent interactions between specific receptors and specific G proteins (G protein activation) or receptor-induced activation of effectors (adenylyl cyclase activity) in living cells [19] . Moreover, we compared the ability of NE, DA, and DA receptor ligands to modulate dynamic mass redistribution (DMR) and to activate MAPK signaling. Lastly, we modeled the binding of DA at α 2A -and α 2C -adrenoceptors, as compared to its binding to the crystallized D 3 receptor. Our results provide conclusive evidence for α 2A -and α 2C -adrenoceptors being not only NE but also DA receptors and common targets for other D 2 -like receptor ligands.
Materials and Methods

DNA Constructs and Transfection
For BRET experiments, human receptor constructs were used for α 2A -and α 2C -adrenoceptors (cDNA Resource Center). The following human G protein constructs were used: Gαi1-, Gαi2-, Gαi3-, Gαo1-, or Gαo2-Renilla luciferase 8 (RLuc8) with RLuc8 inserted at position 91, untagged Gβ1, and Gγ2 fused to full-length mVenus at its N terminus. The Gα-RLuc8 constructs were kindly provided by Céline Galés (INSERM, Toulouse, France). The cAMP sensor using YFPEpac-Rluc (CAMYEL) biosensor was obtained from the American Type Culture Collection (no. MBA-277; ATCC, Manassas, VA, USA) [20] . All the constructs were confirmed by sequencing analysis. A constant amount of plasmid cDNA (0.5 μg Gα-RLuc8, 4.5 μg Gβ1, 5 μg Gγ2-mVenus, and 5 μg receptor) was transfected into HEK-293T cells using polyethylenimine (Sigma-Aldrich) in a 1:2 ratio in 10-cm dishes. Cells were maintained in culture with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and kept in an incubator at 37°C and 5% CO 2 . The transfected amount and ratio among the receptor and heterotrimeric G proteins were tested for optimized dynamic range in drug-induced BRET. HEK-293T cells were also used in BRET experiments for determination of adenylyl cyclase inhibition (see below). For DMR and ERK1/2 phosphorylation assays, Chinese hamster ovary (CHO) cells were grown in minimum essential medium (MEMα; Gibco) supplemented with 2 mM L-glutamine, 100 μg/ml sodium pyruvate, MEM non-essential amino acid solution (1:100), 100 U/ml penicillin/streptomycin, and 5% (v/v) of heat-inactivated fetal bovine serum. These cells were transfected with human α 2A -RLuc8 receptor using polyethylenimine in a 1:2 ratio in 25-cm 2 cell culture flasks. All experiments were performed approximately 48 h after transfection.
BRET
BRET assays were performed to detect receptor ligandinduced events for Gi/o protein activation. Gi/o protein activation assay used RLuc-fused Gαi/o protein subunit and mVenus-fused Gγ2 protein for BRET pair. Receptor and untagged Gβ1 constructs were co-transfected. As reported previously [19, 20] , cells were harvested, washed, and resuspended in phosphate-buffered saline. Approximately 200,000 cells/well were distributed in 96-well plates, and 5 μM coelenterazine H (substrate for luciferase) was added to each well. One minute after the addition of coelenterazine H, ligands (DA, NE, clonidine, quinpirole, 7-OH-PIPAT, and RO-105824) were added to each well. Antagonists were added 10 min before coelenterazine. The fluorescence of the acceptor was quantified (excitation at 500 nm and emission at 540 nm for 1-s recordings) in Mithras LB940 (Berthold Technologies, Bad Wildbad, Germany) to confirm the constant expression levels across experiments. In parallel, the BRET signal from the same batch of cells was determined as the ratio of the light emitted by mVenus (510-540 nm) over that emitted by RLuc (485 nm). G protein activation was calculated as the BRET change (BRET ratio for the corresponding drug minus the BRET ratio in the absence of the drug) observed 10 min after the addition of the ligands. E max values were expressed as the percentage of the effect of each ligand over the effect of NE. BRET curves were analyzed by nonlinear regression using the commercial Prism 4 (GraphPad Software).
DMR
A global cell signaling profile or DMR was measured using an EnSpire Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). This label-free approach uses refractive waveguide grating optical biosensors, integrated into 384-well microplates. Changes in local optical density are measured in a detection zone up to 150 nm above the surface of the sensor. Cellular mass movements induced upon receptor activation are detected by illuminating the underside of the biosensor with polychromatic light and measured as changes in the wavelength of the reflected monochromatic light. These changes are a function of the refraction index. The magnitude of this wavelength shift (in picometers) is directly proportional to the amount of DMR. Briefly, after 24 h of CHO cell transfection with α 2A -RLuc8 receptor, cells were resuspended and seeded at a density of 7000 cells per well in 384-well sensor microplates in 30 μl growing media and cultured for 24 h at 37°C and 5% CO 2 , to obtain monolayers at 70-80% confluency. Before starting the assay, cells were washed twice with assay buffer (MEMα supplemented with 20 mM HEPES, pH 7.15, 0.1% DMSO, and 0.1% BSA) and incubated 2 h in 40 μl per well in the reader at 24°C. Hereafter, the sensor plate was scanned, and a baseline optical signature was recorded for 10 min before adding 10 μl of the agonist dissolved in assay buffer and recorded for 90 min. Kinetic results were analyzed using EnSpire Workstation Software v 4.10.
Adenylyl Cyclase Activity
BRET assays were performed to detect receptor ligandinduced adenylyl cyclase activity. This assay used the CAMYEL biosensor construct which contains RLuc and YFP. The biosensor detects the conformational changes in Epac that are induced upon its binding to cAMP. The conformational change triggered by an increase in cAMP induced by forskolin results in a decrease in BRET due to the relative orientation change between donor and acceptor. A decrease in forskolin-induced cAMP levels is therefore observed as an increase in BRET [21] . To study Gαi-dependent inhibition activity, cells were treated as described above but prestimulated for 10 min with 1 μM forskolin (Sigma-Aldrich), in the presence of 10 μM propranolol 10 min before sample reading to control for activation of endogenous β-adrenergic receptors (see BResults^).
ERK1/2 Phosphorylation
CHO cells were transfected with α 2A -RLuc8 receptor, obtaining a transfection of about 0.3 pmol/mg protein.
The day of the experiment, cells were starved by treating them with serum-free media for 4 h at 37°C. After that, cells were incubated with the indicated agonist for 5 min at 37°C. Then, cells were rinsed with ice-cold phosphatebuffered saline and lysed by adding 200 ml ice-cold lysis buffer (50 mM Tris-HCl (pH 7.4), 50 mM NaF, 150 mM NaCl, 45 mM β-glycerophosphate, 1% Triton X-100, 20 mM phenylarsine oxide, 0.4 mM NaVO 4 , and protease inhibitor cocktail). The cellular debris was removed by centrifugation at 13,000g for 5 min at 4°C, and the protein was quantified. To determine the level of ERK1/2 phosphorylation, equivalent amounts of protein were separated by electrophoresis on a denaturing 10% SDS polyacrylamide gel and transferred onto polyvinylidene fluoride membranes. Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) was then added, and the membrane was rocked for 90 min. The membranes were then probed with a mixture of a mouse antiphospho-ERK1/2 antibody (1:2500; Sigma-Aldrich) and rabbit anti-ERK1/2 antibody that recognizes both phosphorylated and non-phosphorylated ERK1/2 (1:40,000; Sigma-Aldrich) overnight at 4°C. The 42-and 44-kDa bands corresponding to ERK1 and ERK2 were visualized by the addition of a mixture of IRDye 800 (anti-mouse) antibody (1:10,000; Sigma-Aldrich) and IRDye 680 (antirabbit) antibody (1:10,000; Sigma-Aldrich) for 2 h and scanned by the Odyssey infrared scanner (LICOR Biosciences). Band densities were quantified using the scanner software and exported to Excel (Microsoft, Redmond, WA, USA). The level of phosphorylated ERK1/2 isoforms was normalized for differences in loading using the total ERK1/2 protein band intensities.
Radioligand Binding
Brains of male and female sheep of 4-6 months old were freshly obtained from the local slaughterhouse. Brain tissues (cortex and dorsal striatum) and HEK-293T cell suspensions were disrupted with a Polytron homogenizer (PTA 20 TS rotor, setting 3; Kinematica, Basel, Switzerland) for two 5-s periods in 10 volumes of 50 mM Tris-HCl buffer, pH 7.4, containing a proteinase inhibitor cocktail (Sigma, St. Louis, MO, USA). Membranes were obtained by centrifugation twice at 105,000g for 45 min at 4°C. The pellet was stored at − 80°C, washed once more as described above, and resuspended in 50 mM Tris-HCl buffer for immediate use. Membrane protein was quantified by the bicinchoninic acid method (Pierce Chemical Co., Rockford, IL, USA) using bovine serum albumin dilutions as standard. Binding experiments were performed with membrane suspensions at room temperature in 50 mM Tris-HCl buffer, pH 7.4, containing 10 mM MgCl 2 . For competitionbinding assays, membrane suspensions (0.2 mg of protein/ml) were incubated for 2 h with a constant-free conc e n t r a t i o n o f 0 . 9 n M o f t h e α 2 R -a n t a g o n i s t . Non-specific binding was determined in the presence of 10 μM of the non-radiolabeled antagonist RX821002 (for α 2 R) or 30 μM of DA (for D 1 R and D 2 R). In all cases, free and membrane-bound ligands were separated by rapid filtration of 500-μl aliquots in a cell harvester (Brandel, Gaithersburg, MD, USA) through W h a t m a n G F / C f i l t e r s e m b e d d e d i n 0 . 3 % polyethylenimine that were subsequently washed for 5 s with 5 ml of ice-cold 50 mM Tris-HCl buffer. The filters were incubated with 10 ml of Ecoscint H scintillation cocktail (National Diagnostics, Atlanta, GA, USA) overnight at room temperature, and radioactivity counts were determined using a Tri-Carb 2800 TR scintillation counter (PerkinElmer) with an efficiency of 62%.
Binding Data Analysis
Data were analyzed according to the Btwo-state dimer modelô f Casadó et al. [22] . The model assumes GPCR dimers as a main functional unit and provides a more robust analysis of parameters obtained from saturation and competition experiments with orthosteric ligands, as compared with the commonly used Btwo-independent site model^ [22, 23] . In saturation experiments with the radioligand, the model analyzes the total number of radioligand binding sites (B max ; more specifically, it calculates R T , the total number of dimers, where B max = 2R T ), the affinity of the radioligand for the first protomer in the unoccupied dimer (K DA1 ), the affinity of the radioligand for the second protomer when the first protomer is already occupied by the radioligand (K DA2 ), and an index of cooperativity of the radioligand (D CA ). A positive or negative value of D CA implies either an increase or a decrease in affinity of K DA2 versus K DA1 , and its absolute value provides a measure of the degree of increase or decrease in affinity. In competition experiments, the model analyzes the interactions of the radioligand with a competing ligand and it provides the affinity of the competing ligand for the first protomer in the unoccupied dimer (K DB1 ), the affinity of the competing ligand for the second protomer when the first protomer is already occupied by the competing ligand (K DB2 ) or the radioligand (K DAB ), and an index of cooperativity of the competing ligand (D CB ). A positive or negative value of D CB implies either an increase or a decrease in affinity of K DB2 versus K DB1 , and its absolute value provides a measure of the degree of increase or decrease in affinity.
Radioligand competition and saturation curves were analyzed by non-linear regression using the commercial GraFit curvefitting software (Erithacus Software, Surrey, UK), by fitting the binding data to the mechanistic two-state dimer receptor model, as described in detail elsewhere [24] . The equation describing the saturation experiment with the radioligand A in noncooperative conditions (K DA2 / K DA1 = 4) is as follows:
, where A represents the radioligand concentration. To calculate the macroscopic equilibrium dissociation constants from competition experiments, the following general equation must be applied:
, where B represents the assayed competing compound concentration (F). For A, the non-cooperative and non-allosteric modulation between A and B, the equation is simplified due to the fact that K DA2 = 4K DA1 and
). For A and B, the non-cooperative and nonallosteric modulation between A and B, the equation can be simplified due to the fact that K DA2 = 4K DA1 , K DB2 = 4K DB1 , and
).
Statistical Analysis
In binding assays, goodness of fit was tested according to reduced chi-square value given by the regression program. The test of significance for two different model population variances was based upon the F-distribution. Using this F-test, a probability greater than 95% (p < 0.05) was considered to be the criterion to select a more complex model (cooperativity) over the simplest one (non-cooperativity). In all cases, a probability of less than 70% (p > 0. 
Homology Modeling of α 2A -and α 2C -Adrenoceptors
Homology models of α 2A -and α 2C -adrenoceptors were constructed from multiple templates using RosettaCM [25] with a protocol previously described [26] . Sequences of each adrenoceptor were aligned with sequences of the following receptors: D 3 (PDB ID: 3PBL [27] ), β 1 (PDB ID: 4BVN [28] ), β 2 (PDB ID: 2RH1 [29] ), 5HT 1B (PDB ID: 4IAR [30] ), and 5HT 2B (PDB ID: 4IB4 [31] ) using BLAST and were modified to ensure alignment of secondary structure elements and conserved residues. The N-terminus was truncated through residues 28 and 46 and the C-terminus was deleted after residues 442 and 456, respectively. Additionally, the long intracellular loop 3 was deleted at residues 229-372 in α 2A and 243-381 in α 2C and replaced with an eight-residue polyGly linker. These sequences were threaded onto each template and hybridized to generate full-length, energy-minimized structures. Models were clustered using automatic radius detection in Rosetta, and the low-energy cluster centers from the top five clusters were selected for additional modeling.
Protein-Ligand Docking
The tridimensional structure of DA was obtained from PubChem (ID 3713609). Conformers of DA were generated using the BCL [32] . To identify the initial starting coordinates for ligand docking, homology models were aligned with the crystal structure of β 2 -adrenoceptor (PDB ID: 4LDO (33)) and DA was aligned with the crystallized ligand. Ligand docking was performed in RosettaLigand using the small perturbation of ligand position protocol and swapping of ligand conformers [33, 34] . One thousand models for each proteinligand complex were generated. Models were sorted initially by total energy and then culled to the top 5% of models by interface energies for analysis. Per-residue ΔΔG analysis was performed to identify residues involved in ligand binding.
Results
Binding of DA and DA Receptor Ligands to α 2 -Adrenoceptors in Cortical and Striatal Tissue
First, we analyzed the ability of NE, DA, the non-selective α-adrenoceptor agonist clonidine, the non-selective D 2 8), respectively. This implies that the density of α 2 -adrenoceptors in the cortex, which is mostly represented by α 2A -adrenoceptors [3, 4] , is three times higher than that in the striatum, which expresses similar densities for both α 2A -and α 2C -adrenoceptors [8] . To test the binding selectivity of [ Table 1 . In both tissues, NE, DA, and clonidine showed high affinity for [ 3 H]RX821002 binding sites with an order of potency of clonidine > NE > DA (Fig. 2) . The three ligands showed negative cooperativity (negative D CB values). The affinity of NE was higher in the cortex than in the striatum, with higher striatal K DB1 , K DB2 , and D CB values (stronger negative cooperativity) ( Table 1 ). The affinity of DA was very similar in both tissues, with similar K DB1 values and a moderately but significantly higher K DB2 value in the striatum, resulting in similar D CB values ( Table 1 ). The affinity of clonidine was also higher in the cortex, with a significantly higher striatal K DB1 value and similar D CB values (Table 1) . 7-OH-PIPAT and quinpirole also displaced [ cortex, and it was almost ten times lower than the cortical K DB2 value (Table 1) . Quinpirole also showed differences in the binding parameters between the cortex and striatum, such as a lower K DB1 value but negative cooperativity in the striatum. Finally, RO-105824 also displaced [ (Fig. 1b) . The equilibrium binding parameters are shown in Table 2 . Both NE and DA showed negative cooperativity ( Fig. 1 ) with negative D c values ( Table 2 ). The affinity of DA for the first protomer of the D 2 -like receptor dimer (K DB1 ), mostly represented by the D 2 R subtype in the dorsal striatum [35] , was similar to the affinity for α 2 -adrenoceptors and D 1 -like receptors (Fig. 1 , Table 2 ). The affinity of DA for the second protomer (K DB2 ) of the D 1 -like receptor was even about ten times lower than that for the α 2 -adrenoceptors and D 2 -like receptors (stronger negative cooperativity; see Table 2 ). On the other hand, the affinity of NE for α 2 -adrenoceptors in the striatum, represented by α 2A -and α 2C -adrenoceptors, was significantly higher than that for dopamine receptors (Fig. 1 ). Specifically, NE had an affinity for DA receptors about 60-fold lower than that for α 2 -adrenoceptors ( Table 2 , Fig. 1 ). We can therefore assume that extracellular physiological levels of DA that are The G protein activation BRET assay (see BMaterials and Methods^) was used to determine the potency and efficacy of the above-studied ligands to activate α-adrenoceptors in HEK-293T cells transfected with α 2A -or α 2C -adrenoceptor and one of the five different RLuc-fused Gαi/o subunits (Gαi1, Gαi2, Gαi3, Gαo1, and Gαo2) with Venus-fused Gγ2 protein as BRET acceptor pair. The amount of Gαi/o subunits transfected produced values between 0.5 and 1 million luminescence units (arbitrary units). Previously, we found that luminescence values between 200,000 and 1.5 million did not produce a significant alteration of the E max of drug-induced BRET. Moreover, the levels of α 2 -adrenoceptor were around 2 pmol/mg protein. We also previously reported that, using the same cell line and assay conditions, neither DA or NE produces a significant BRET change when transfected with the same fused G protein subunits but without receptor co-transfection [19] . These transfected receptor levels were only slightly higher than those obtained in binding experiments in the sheep brain cortex (see above). A concentration response of the ligand-induced change in BRET values allows to determine the potency as well as the relative efficacy (to NE) at α 2A -and α 2C -adrenoceptor-mediated G protein activation. Results were largely in agreement with the values obtained with binding experiments, considering that cortical values should represent ligand binding parameters of α 2A -adrenoceptors, while striatal values represent combined ligand binding parameters for both α 2A -and α 2C -adrenoceptors. NE was more potent at α 2A -than at α 2C -adrenoceptor, except for Gαi2 and Gαi3. On the other hand, DA had similar potencies at both adrenoceptors, except for Gαi2 and Gαo1. At both α 2A -and α 2C -adrenoceptors, DA showed high potency and efficacy as compared with NE (Figs. 3 and 4 , Tables 3 and 4), although DA was always less potent than NE. The relative DA/NE potency depended on the α-adrenoceptor and on the Gαi/o subtype (see Table 3 ). Therefore, the potencies of DA at activating α 2A -adrenoceptor varied from about 15-fold lower, for Gαi1, to about 30-fold lower, for Gαo1. On the other hand, the potencies of DA as compared to NE at activating α 2C -adrenoceptor were very close to those of NE and they varied from less than twofold lower, for Gαi1, to about 70-fold lower, for Gαi3 (Table 3) .
The prototypical non-selective α-adrenoceptor agonist clonidine only showed a significantly higher potency at α 2A -than at α 2C -adrenoceptors for Gαo1 and Gαo2 (Table 3 ). An additional difference as compared to NE was that clonidine behaved as a full agonist at α 2A -and as a partial agonist at α 2C -adrenoceptor, except for Gαi2 and Gαi3 (Figs. 3 and 4 , Table 4) . Intriguingly, the level of efficacy of clonidine for α 2C -adrenoceptor varied significantly with the associated Gαi/o protein subtypes, from no decrease for Gαi2 to a very significant loss of efficacy for Gαo1 (Table 4) . Previous studies have already reported a partial agonism of clonidine at α 2 -adrenoceptors, but with disparate results [36, 37] , which, at least for α 2C , could be related to the Gαi/o protein subtypes involved. In summary, the differences in the respective potency values of NE, clonidine, and DA for α 2A -and α 2C -adrenoceptors in the G protein activation BRET experiments correlate with the higher affinities of NE and clonidine in the cortex and similar affinities of DA in the cortex and striatum.
The non-selective D 2 -D 3 -D 4 receptor agonist quinpirole and the selective D 3 receptor agonist 7-OH-PIPAT also activated α 2A -and α 2C -adrenoceptors, but with very different profiles (see Figs. 3 
and 4, Tables 3 and 4). 7-OH-PIPAT
behaved as a low efficacious agonist at α 2A -adrenoceptors for the Gαi2 subtype. On the other hand, 7-OH-PIPAT behaved as a partial agonist at α 2C -Gαi1 complexes but as a full agonist with the other α 2C -Gαi/o complexes. This D 3 receptor agonist, at α 2A -adrenoceptor, was, in general, as potent as DA and, for both Gαo subtypes, was as potent α 2C -adrenoceptor agonist as NE. In contrast, quinpirole showed a weak potency (submicromolar range) but also behaved as a partial or full agonist depending on the Gαi/o subtype. At α 2A , quinpirole behaved as a partial agonist for Gi1, Gi2, and Gi3 and a full agonist for Go1 and Go2, whereas at α 2C , it behaved as a partial agonist for all G protein subtypes except for Gi3 (full agonist) and showed no activity when coupled with Gαi1. As shown in Fig. 5 , yohimbine, a non-selective α 2 -adrenoceptor antagonist, completely blocked the effect of 7-OH-PIPAT and quinpirole at both α 2A -and α 2C -adrenoceptors (for Gαo1), demonstrating the specificity of the α 2 -adrenoceptor signal produced by both agonists. The potency values of 7-OH-PIPAT and quinpirole in G protein activation BRET experiments correlate with the nanomolar and submicromolar affinities, respectively, as seen in binding assays with brain membranes. Moreover, the higher potencies of 7-OH-PIPAT for α 2C -versus α 2A -adrenoceptors also correlate with our binding results due to the fact that 7-OH-PIPAT showed negative Tables 1 and 2 for EC 50 and E max values and statistical analysis) cooperativity in the cortex but not in the striatum. For quinpirole, however, it would be difficult to establish correlations with results from binding assays due to its low efficacy in BRET assays, which might lead to inaccurate values (Table 3 , in parentheses, and Table 4 , in italics). Finally, and unexpectedly, the selective D 4 receptor agonist RO-105824 (with Tables 1 and 2 for EC 50 and E max values and statistical analysis) (Figs. 3 and 4) . To confirm the binding of this putative selective D 4 receptor ligand to α 2A -and α 2C -adrenoceptors, they were tested for their ability to modify the effect of clonidine. RO-105824 did counteract the respective full and partial agonistic effect of clonidine (1 μM) at the α 2A -and α 2C -adrenoceptors coupled to Gαo1 (Fig. 5c, d) . Therefore, the results of BRET and radioligand binding experiments disclosed a previously unknown additional role of the D 4 receptor agonist RO-105824, as a very potent and lowefficacious ligand for α 2 -adrenoceptors at Gαi/o activation. We also determined the effect of DA and synthetic DA receptor ligands on a DMR label-free assay in CHOtransfected cells. This approach detects changes in local optical density due to cellular mass movements induced upon receptor activation (see the BMaterials and Methods^section), and DMR responses primarily reflect G protein-dependent signaling in living cells, since it can be abrogated by toxins or inhibitors of the G proteins involved [38] . DA was as capable as NE at activating cellular signaling in CHO cells transfected with α 2A -RLuc8 receptor (Fig. 6a) . The amount of α 2A -RLuc8 receptor expressed was about 0.3 pmol/mg protein. DA and NE activation decreased by adding the α 2A R-antagonist BRL 44408, indicating the specificity of the cell activation through α 2A -receptor. The synthetic DA receptor ligands 7-OH-PIPAT, quinpirole, and RO-105824 at 300 nM were also able to produce a significant response (Fig. 6b) , substantially lower for RO-105824, which correlates with the G protein activation BRET assays (Fig. 3) . These results indicate that DA and synthetic DA receptor ligands are also α 2 -adrenoceptor ligands able to activate Gαi/o proteins, which correlate with their efficacy with DMR.
α 2A -and α 2C -Adrenoceptor-Mediated Effects of NE and DA on Adenylyl Cyclase Activity NE-and DA-induced changes in adenylyl cyclase activity were also analyzed by measuring cAMP levels in intact cells transiently transfected with α 2A -or α 2C -adrenoceptor, using the CAMYEL BRET biosensor (see the BMaterials and Methodsŝ ection and ref. 21 ). HEK-293T cells have been reported to endogenously express β-adrenoceptors [39] . Accordingly, we recently reported that NE, in non-transfected HEK-293T cells, stimulated a Gs-mediated cAMP increase, which could be completely inhibited by the selective β-adrenergic blocker propranolol (10 μM) (ref. 19 ; the same website address as above). Therefore, the β-adrenoceptor antagonist propranolol was added throughout the cAMP detection experiments. As shown in Fig. 7 , NE and DA produced an increase in BRET, corresponding to a decrease in forskolin-induced cAMP accumulation for both α 2A -and α 2C -adrenoceptor-transfected cells. The decrease in adenylyl cyclase activity by NE and DA provided apparent half maximal effective concentration (EC 50 ) values that were qualitatively and quantitatively close to those observed with the Gi/o activation BRET assays, as NE was more potent than DA at α 2A and α 2C (1.4 ± 0.2 and 7 ± 4 nM for NE and 140 ± 40 and 90 ± 20 nM for DA, respectively). The putative Gi/o-dependent effects mediated by NE and DA were blocked by the non-selective α 2 -adrenoceptor antagonist yohimbine, confirming the receptor specificity of the signal (Fig. 7) . In Table 4 Efficacy of NE, DA, clonidine, 7-OH-PIPAT, and quinpirole obtained from G protein (Figs. 3 and 4) . E max values were obtained from a sigmoidal concentration-response function adjusted by non-linear regression analysis and are expressed as means ± SEM of 3 to 11 experiments performed in triplicate. In italics, values of E max are lower than 50%. Statistical differences between NE and the other ligands for each receptor and Gαi/o protein subtype were calculated by one-way ANOVA, followed by Dunnett's post hoc test ND not detectable *p < 0.05; **p < 0.01; ***p < 0.001 addition, cells were treated with pertussis toxin which catalyzes the ADP ribosylation of the αi subunits of the heterotrimeric G protein, preventing its interaction with the receptor. As expected, pertussis toxin treatment selectively eliminated the initial, therefore Gi-dependent, component of the NE-and DA-mediated effects (Fig. 7) . Surprisingly, NE and DA showed inverted U-shaped concentration-response curves with a putative Gs-dependent profile at high ligand concentrations for both α 2A -and α 2C -adrenoceptor-transfected cells (Fig. 7) . These results could be explained by considering previous studies showing that α 2 -adrenoceptors functionally couple not only to Gi/o proteins but also to Gs [40] [41] [42] [43] [44] . Typically, the agonist concentrations necessary to elicit detectable stimulation of adenylyl cyclase are significantly higher than those for inhibition. Equivocal results were published by Zhang et al. [16] when comparing the effect of NE and DA on forskolin-induced adenylyl cyclase activation. In their cell systems, NE seemed to predominantly activate Gs with α 2A and Gi with α 2C , while DA would predominantly activate Gi with both receptors, but at high micromolar concentrations. In contrast, our experiments show that NE and DA follow the same differential concentration-dependent effects on Gi/o and Gs activation and, at least, at 10 and 100 μM, DA and NE promoted Gs activation mediated by both α 2A -and α 2C -adrenoceptors (Fig. 7) .
α 2A -and α 2C -Adrenoceptor-Mediated Effects of NE, DA, and Synthetic DA Receptor Ligands on ERK1/2 Phosphorylation Finally, we studied the ability of DA and synthetic DA receptor ligands to produce MAPK activation. First, we analyzed the increase on ERK1/2 phosphorylation produced by 300 nM of NE in CHO cells transfected with α 2A -RLuc8 receptor. This NE concentration increased ERK1/2 phosphorylation levels by threefold over basal, and this effect was similar to that produced by 1 μM of DA (Fig. 8) . Next, we demonstrated that the synthetic DA receptor ligands 7-OH-PIPAT, quinpirole, and RO-105824, at 1 μM, were also able to produce MAPK activation (Fig. 8) . At this concentration, the efficacy of RO-105824 was similar to that of the other ligands. Together with its very low efficacy disclosed on G protein activation and DMR assays, these results indicate that RO-105824 is a biased agonist of α 2A -adrenoceptors with functional selectivity for G protein-independent signaling. In summary, adenylyl cyclase activity and ERK1/2 phosphorylation experiments confirm the results from radioligand binding and G protein activation assays, indicating that DA and synthetic DA receptor ligands are efficacious α 2 -adrenoceptor agonists.
Structural Basis for DA at α 2A -and α 2C -Adrenoceptors
An examination of the binding mode of DA to the adrenoceptors was undertaken to model the activity seen in the biological assays. To generate models of α 2A -and α 2C -adrenoceptors, we used the RosettaCM [25] application within the Rosetta suite of macromolecular modeling tools [26, 45] . This method relies on the optimal alignment of a target sequence with multiple template structures obtained from the PDB which are hybridized together to generate novel models. We submitted the sequence of α 2A and α 2C to BLAST-P and found the top five crystal templates by sequence identity to be the DA D 3 receptor [27] , β 1 -adrenoceptor [28] , β 2 -adrenoceptor [29] , serotonin 5-HT 1B receptor [30] , and serotonin 5-HT 2B receptor [31] . Interestingly, the α 2 -adrenoceptors have more sequence identity in the transmembrane helical bundle with the D 3 receptor than with the related β-adrenoceptors. RosettaCM yielded an ensemble of lowenergy models of the receptors, which were clustered by structural similarity. The top five cluster centers were included in the docking studies to account for structural diversity and uncertainty in homology modeling. To understand DA activation, we first examined the binding of DA to the D 3 receptor, the only crystal structure of a DA receptor to date. As there is not a co-crystal structure of DA/D 3 receptor, we first docked DA to the D 3 receptor using RosettaLigand [33] . The starting coordinates of epinephrine bound to the β 2 -adrenoceptor [46] were used to place DA for docking. Binding pocket analysis identified residue D3.32 interacting with the primary amine in DA and the catechol hydroxyls interacting with S5.42 and S5.46. Important hydrophobic packing against the central portion of DA was achieved by V3.33, H6.55, and F6.51. These are the same interactions that were previously identified in a molecular dynamics simulation of DA binding at D 3 receptor [47] . Comparing the residues at these positions to those in α 2A -and α 2C -adrenoceptors revealed identity at all residues except position 6.55, in which the His has been replaced with a Tyr in both α 2A -and α 2C -adrenoceptors. Docking results of DA at either α 2A or α 2C also identified many of these same residues as critical for binding. Particularly, D3.32, V3.33, S5.42, and F6.51 were present in all receptor models contributing more than − 0.4 Rosetta energy units each to the binding of DA (Fig. 9) . Residues S5.46 and Y6.55 were also present in all receptor binding modes though contributions varied depending on which receptor type. These results coupled with those from the biological assays provide a strong structural reasoning behind the activity of DA at the α 2A -or α 2C -adrenoceptors.
Discussion
Previous studies reported DA as a potential α 2 -adrenoceptor ligand on the basis of radioligand binding experiments in transfected mammalian and insect cell lines [16, 17] and in bird and rat brains [18] and also from autoradiographic experiments in tissues [18] . Furthermore, DA has been reported to decrease cAMP intracellular levels in transfected mammalian cell lines but only throughout α 2C -adrenoceptors, not α 2A -adrenoceptors, and at concentrations much higher than NE (EC 50 in the micromolar range) [18] .
In our study, we show that α 2A -and α 2C -adrenoceptors can bind DA at concentrations in the same order than NE, suggesting that they could be activated by DA at in vivo concentrations. First, our results demonstrate that endogenous DA, and also common synthetic DA receptor ligands, binds to α 2 -adrenoceptors with moderate to high affinity in the mammalian brain. Second, the affinity of DA for α 2 -adrenoceptors is in the same range as for D 1 -like and D 2 -like receptors, suggesting that endogenous The most conclusive demonstration that DA is an α 2 -adrenoceptor ligand comes from the results obtained with binding and G protein activation BRET assays, where the affinities or potencies of DA for α 2 -adrenoceptors were found to be very similar or even higher than for D 1 -like and some subtypes of D 2 -like receptors [19] . Particularly, the EC 50 values of DA for α 2A -and α 2C -adrenoceptors (5-170 nM) were consistently lower across all Gi/o protein subtypes as compared with the EC 50 values (130-400 nM) for the predominant striatal D 2 -like receptor D 2L [19] . Taking into account that the levels of tonic extracellular DA are 20-30 nM (with peaks of 500 nM) [48] , DA could reach sufficient extracellular concentration to activate α 2A -and α 2C -adrenoceptors in the striatum, irrespective of the maximal concentration of extracellular NE. In fact, striatal DA release sites are designed for transmitter spillover [49] and most striatal DA receptors are primarily extrasynaptic [50, 51] , as well as striatal adrenoceptors, based on the mismatched low NE innervation [7] [8] [9] [10] [11] . Although the specific functional role of the DAsensitive α 2 -adrenoceptors in neuronal striatal function remains to be established, a previous study suggests that they might mediate an inhibitory modulatory role of the Gs/olfcoupled striatal adenosine A 2A and DA D 1 receptors [14] .
The possibility of DA-mediated activation of α 2A -and α 2C -adrenoceptors in extrastriatal areas should not, however, be underestimated. Cortical α 2A -adrenoceptors are most probably able to be activated by DA, particularly in the prefrontal cortex, which receives a rather dense DA innervation [52] . In fact, there is recent evidence for the localization of α 2A -adrenoceptors in the cortical terminals from mesencephalic DA neurons [53] , which could play a role as BDA autoreceptors.^But, there is also evidence for the localization of both α 2A -and α 2C -adrenoceptors in the soma and dendrites of the mesencephalic DA cells of both substantia nigra and ventral tegmental areas [53, 54] . Apart from the NE input, these α 2A -and α 2C -adrenoceptors should be able to act as DA autoreceptors that control the non-synaptic somatodendritic DA release [49] . Adding the present results to our recent study that also indicates a significant role of NE as a Gi/o-coupled D 2 -like receptor agonist [19] , we could state that Gi/o-coupled adrenoceptors and DA receptors should probably be considered as members of one Bfunctional^family of catecholamine receptors. A general consideration from the DA and D 2 -like receptor ligand sensitivity of cortical α 2A -adrenoceptors is that it should also be involved in the cognitive-enhancing effects associated with their activation, with possible implications for attention deficit hyperactivity disorder [55] .
Molecular modeling of DA binding to the various receptors provides a likely binding hypothesis for the results obtained in the biological assays. Of note is the striking similarity between the ligand binding pocket of the D 3 receptor and that of α 2A -and α 2C -adrenoceptors. Many of the residues that line the binding pocket are identical or chemically well conserved. Given this similarity, it was perhaps unsurprising that the docking of DA at α 2A and α 2C was nearly identical to DA binding to the D 3 receptor. The lower potency of DA at α 2A -and α 2C -adrenoceptors compared to NE seems to depend on a lower number of strong interactions as compared to those between DA and D 3 receptors. The pocket may have evolved to bind the slightly bulkier NE and, therefore, is not of an ideal size for DA. However, the differences may also be due to the lower resolution of binding predictions for a comparative model as opposed to a crystal structure. Despite this, the Another major finding of the present study is that α 2A -and α 2C -adrenoceptors are also common targets for compounds previously characterized as D 2 -like receptor ligands. Particularly striking was the ability of prototypical D 3 and D 4 receptor agonists 7-OH-PIPAT and RO-105824 to bind with high affinity to α 2A -and α 2C -adrenoceptors, which might call for revisiting results of previous studies using these compounds. Furthermore, these two compounds and the other DA-synthetic ligands assayed, as well as NE, were able to activate ERK1/2 phosphorylation by binding to α 2 -adrenoceptors. The final pharmacological profile of RO-105824 was that of a potent biased agonist for α 2A -adrenoceptor with functional selectivity for a G protein-independent signaling. On the other hand, based on BRET experiments, both potency and efficacy dependence on the receptor and the Gαi/o protein subtype were the norm for all ligands, including the endogenous neurotransmitters. We already described that NE and DA show different receptor-and Gαi/o subtype-dependent potencies of D 2 -like receptor-mediated G protein activation [19] . The present results extend these findings to other receptors and to non-endogenous ligands, as well as to differences in efficacy. Even though G proteins of the Gαs-Gαolf family do show contrasting brain expression pattern [56] , to our knowledge, no clear region-specific pattern of mRNA expression for Gαi/o protein subtypes has been reported. Detailed characterization of the expression patterns for Gαi/o protein subtypes would then be central to determine their role in α 2A -and α 2C -adrenoceptor activation and thus their possible specific targeting with Gαi/o subtype functionally selective compounds.
In conclusion, DA is a potent and efficacious ligand at α 2 -adrenoceptors, which modulates forskolin-induced adenylyl cyclase activity and ERK1/2 phosphorylation. The concentration required for these effects is in the range of that for activating D 2 -like and D 1 -like receptors, indicating that these receptors are members of one functional family of catecholamine receptors. Our results provide a clear answer to the mismatch between the low striatal NE innervation and the high density of striatal α 2 -adrenoceptors, which behave as functional DA receptors.
